Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | DHODH | Q02127 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10860624 | 0.88 | MEN1 (0.60) | MEN1KMT2ADHODHGAACYP3A4 | |
| SCHEMBL2970561 | 0.86 | MEN1 (0.75) | MEN1KMT2ADHODHGAACYP3A4 | |
| SCHEMBL2485251 | 0.86 | MEN1 (0.59) | MEN1KMT2ADHODHGAACYP3A4 | |
| SCHEMBL22492470 | 0.84 | DHODH (0.66) | MEN1KMT2ADHODHGAACYP3A4 | |
| SCHEMBL7432042 | 0.84 | MEN1 (0.59) | MEN1KMT2ADHODHGAACYP3A4 | |
| SCHEMBL396592 | 0.83 | KDM4E (0.66) | MEN1KMT2ADHODHGAACYP3A4 | |
| SCHEMBL17128366 | 0.81 | DHODH (0.74) | MEN1KMT2ADHODHGAACYP3A4 | |
| SCHEMBL18529096 | 0.80 | MEN1 (0.54) | MEN1KMT2ADHODHGAACYP3A4 | |
| SCHEMBL17241561 | 0.79 | DHODH (0.62) | MEN1KMT2ADHODHGAACYP3A4 | |
| SCHEMBL31373000 | 0.79 | MEN1 (0.56) | MEN1KMT2ADHODHGAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2037739-B1 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | disclosed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | disclosed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | CHRM1, OPRL1, MTNR1A | MEN1 2827/4885KMT2A 1268/4885DHODH 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.